Claims for Patent: 4,216,211

Summary for Patent: 4,216,211

Title:	Therapeutic composition
Abstract:	Phosphonate compounds are employed in the treatment of hypoxias and ischemic tissue diseases.
Inventor(s):	Francis; Marion D. (Cincinnati, OH)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	05/847,190
Patent Claims:	1. A process for increasing the level of 2,3-diphosphoglycerate in the blood of a human or lower animal in need of such treatment, comprising administering to said human or lower animal sufficient organophosphonate compound selected from the group consisting of vicinal organophosphonates of the formula ##STR4## and geminal organophosphonates of the formula ##STR5## and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to about 10; R, R.sub.1 and R.sub.2 are H,--CH.sub.2 OH, C.sub.1 -C.sub.20 alkyl or cycloalkyl, C.sub.2 -C.sub.20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH.sub.2 COOH, --CH.sub.2 PO.sub.3 H.sub.2, --CH(PO.sub.3 H.sub.2) (OH) or --CH.sub.2 CH(PO.sub.3 H.sub.2).sub.2 ; R.sub.3 is H, C.sub.1 -C.sub.20 alkyl or cycloalkyl, C.sub.2 -C.sub.20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH.sub.2 COOH, --CH.sub.2 PO.sub.3 H.sub.2, --CH(PO.sub.3 H.sub.2) (OH) or --CH.sub.2 CH(PO.sub.3 H.sub.2).sub.2 ; and R.sub.4 is H, lower alkyl, amino, benzyl, halogen, OH, --CH.sub.2 COOH, --CH.sub.2 PO.sub.3 H.sub.2 or --CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2 to increase the blood level of said 2,3-diphosphoglycerate. 2. A process according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid and the pharmaceutically-acceptable salts and esters thereof. 3. A process according to claim 2 wherein the organophosphonate compound is a sodium salt of ethane-1-hydroxy-1,1-diphosphonic acid. 4. A process according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of methanediphosphonic acid and the pharmaceutically-acceptable salts and esters thereof. 5. A process according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of methanedichlorodiphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.